BioSpace News Archive

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.

Roche announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Premarket Approval (PMA) supplement for the cobas® EGFR Mutation Test v2 to be used as a companion diagnostic test (CDx) with TAGRISSO® for first line treatment of patients diagnosed with metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.

SMI is excited to announce its continued leadership and innovation in the in vivo pressure measurement space.

Milestone achieved under the highly successful strategic alliance Evotec and Bayer entered in October 2012.

Orphan drug designation will give the KL1333 program extra access to regulatory and scientific advice and interactions at the FDA

Sempre works with health plans to reward their membership’s positive choices and actions.

MAXIMUS announced that its customer contact center operations in Georgia and New Jersey have received the 2018 Top Contact Center Award in five different categories by BenchmarkPortal, Inc.

BioCardia is a leader in cardiovascular regenerative medicine.

Canopy Growth Corporation and the Yukon Liquor Corporation announced that the Company has entered into an agreement to supply Yukon with high-quality cannabis products to serve the upcoming adult retail market.

Facing unprecedented challenges associated with Brexit, on 13 April the UK’s major clinical research organizations (CROs) met with the Rt Hon Hilary Benn (Labour - Leeds Central) to tour Covance’s research facilities in Leeds and discuss the implications of the impending separation from the European Union.